A Phase 3 interventional study of Leuprolide Acetate (LA) in Central Precocious Puberty (CPP), sponsored by AbbVie. Completed at 18 sites in 2 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2024-05-29.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.
Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 11th largest by enrollment, is the only one that started in 2018, is one of 6 in phase 3, and was the 10th registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:
LG Chem · Sites in Korea, Republic of
Ages up to 10
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 4–10
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 1 started in 2018.
This study's enrollment of 45 is below the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 68 across the 14 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 2 studies filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing leuprolide in Puberty, Precocious, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) or who have been previously treated with a GnRHa.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received leuprolide acetate (LA) 45 mg every 6 months administered as an intramuscular injection for up to 144 weeks.
Drug: Leuprolide Acetate (LA)
Administered intramuscularly as an injection
Also known as: Lupron Depot
Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24
Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.
Time frame: Week 24 (prior to the Week 24 dose); samples for LH measurement were taken 30 and 60 minutes after the stimulation test injection.
Part 1: Percentage of Participants With Suppression of Peak GnRHa-stimulated LH to Less Than 4 mlU/mL at Weeks 12, 20, 44, and 48
Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.
Time frame: Weeks 12, 20, 44, and 48 (prior to Week 48 dose); samples for LH measurement were taken 30 and 60 minutes after the stimulation test injection.
Part 1: Percentage of Female Participants With Suppression of Basal Estradiol to < 20 pg/mL at Weeks 12, 20, 24, 44, and 48
Estradiol concentrations were measured from blood samples taken at each study visit prior to stimulation testing (and prior to study drug administration at Weeks 24 and 48).
Time frame: Weeks 12, 20, 24, 44, and 48
Part 1: Percentage of Male Participants With Suppression of Basal Testosterone to < 30 ng/dL at Weeks 12, 20, 24, 44, and 48
Testosterone concentrations were measured from blood samples taken at each study visit prior to stimulation testing (and prior to study drug administration for Weeks 24 and 48).
Time frame: Weeks 12, 20, 24, 44, and 48
Parts 1 and 2: Percentage of Participants With Suppression of the Physical Signs of Puberty
Breast development in females and testicular volume or genital development in males was assessed using modified Tanner staging, on a scale from Stage 1 (prepubertal) to Stage 5 (adult characteristics). Females: Suppression is defined as regression or no progression of breast development according to modified Tanner staging. Males: Suppression is defined as regression or no progression in testicular volume and genital staging according to modified Tanner staging.
Time frame: Part 1: Weeks 24 and 48; Part 2: Weeks 72, 96, 120, and 144
Parts 1 and 2: Change From Baseline in Incremental Growth Rate
Growth rate (height in centimeter/year) was calculated both prior to treatment in the study and during the study. For Baseline calculation a historical measurement of height at least 6 months prior to Screening and the Screening value was used.
Time frame: Part 1: Baseline and Weeks 4, 12, 20, 24, 44, and 48; Part 2: Weeks 72, 96, 120, and 144
Parts 1 and 2: Ratio of Change From Baseline in Bone Age to Change From Baseline in Chronological Age
Bone age was assessed from radiographs of the hand and wrist by a central imaging vendor using the BoneXpert automated system. A ratio less than 1 indicates less advancement of bone age compared to chronological age.
Time frame: Part 1: Baseline and Weeks 24 and 48; Part 2: Weeks 72, 96, 120, and 144
Part 2: Percentage of Participants With Maintenance of Suppression of GnRHa-stimulated LH (< 4 mlU/mL)
Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.
Time frame: Weeks 72, 96, 120, and 144
Part 2: Percentage of Female Participants With Maintenance of Suppression of Basal Estradiol to < 20 pg/mL
Estradiol concentrations were measured from blood samples taken at each study visit prior to stimulation testing.
Time frame: Weeks 72, 96, 120, and 144
Part 2: Percentage of Male Participants With Maintenance of Suppression of Basal Testosterone to < 30 ng/dL
Male participants with maintenance of suppression of testosterone to \< 30 ng/dL are assessed
Time frame: Weeks 72, 96, 120, and 144
Participants were enrolled at 16 sites in the United States including Puerto Rico. The study enrolled pediatric participants with central precocious puberty (CPP) who were either naïve to treatment with a gonadotropin-releasing hormone receptor agonist (GnRHa) or who had been previously treated with a GnRHa.
| Milestone | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve |
|---|---|---|
| Started | 18 | 27 |
| Completed | 8 | 20 |
| Not completed | 10 | 7 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Other, not specified | 8 | 2 |
Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.
| percentage of participants | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Leuprolide Acetate - Overall |
|---|---|---|---|
| Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24 | 94.4 (72.7 to 99.9) | 81.5 (61.9 to 93.7) | 86.7 (73.2 to 95.0) |
Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.
| percentage of participants | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Leuprolide Acetate - Overall |
|---|---|---|---|
| Week 12 | 83.3 (58.6 to 96.4) | 88.9 (70.8 to 97.7) | 86.7 (73.2 to 95.0) |
| Week 20 | 94.4 (72.7 to 99.9) | 85.2 (66.3 to 95.8) | 88.9 (76.0 to 96.3) |
| Week 44 | 88.9 (65.3 to 98.6) | 88.9 (70.8 to 97.7) | 88.9 (76.0 to 96.3) |
| Week 48 | 83.3 (58.6 to 96.4) | 92.6 (75.7 to 99.1) | 88.9 (76.0 to 96.3) |
Estradiol concentrations were measured from blood samples taken at each study visit prior to stimulation testing (and prior to study drug administration at Weeks 24 and 48).
| percentage of participants | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Leuprolide Acetate - Overall |
|---|---|---|---|
| Week 12 | 100.0 (79.4 to 100.0) | 95.5 (77.2 to 99.9) | 97.4 (86.2 to 99.9) |
| Week 20 | 100.0 (79.4 to 100.0) | 95.7 (78.1 to 99.9) | 97.4 (86.5 to 99.9) |
| Week 24 | 100.0 (80.5 to 100.0) | 95.2 (76.2 to 99.9) | 97.4 (86.2 to 99.9) |
| Week 44 | 100.0 (80.5 to 100.0) | 100.0 (85.2 to 100.0) | 100.0 (91.2 to 100.0) |
| Week 48 | 100.0 (79.4 to 100.0) | 100.0 (85.8 to 100.0) | 100.0 (91.2 to 100.0) |
Testosterone concentrations were measured from blood samples taken at each study visit prior to stimulation testing (and prior to study drug administration for Weeks 24 and 48).
| percentage of participants | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Leuprolide Acetate - Overall |
|---|---|---|---|
| Week 12 | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | 100.0 (29.2 to 100.0) |
| Week 20 | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) | 100.0 (29.2 to 100.0) |
| Week 24 | 100.0 (2.5 to 100.0) | 100.0 (29.2 to 100.0) | 100.0 (39.8 to 100.0) |
| Week 44 | 100.0 (2.5 to 100.0) | 100.0 (29.2 to 100.0) | 100.0 (39.8 to 100.0) |
| Week 48 | 100.0 (2.5 to 100.0) | 100.0 (29.2 to 100.0) | 100.0 (39.8 to 100.0) |
Breast development in females and testicular volume or genital development in males was assessed using modified Tanner staging, on a scale from Stage 1 (prepubertal) to Stage 5 (adult characteristics). Females: Suppression is defined as regression or no progression of breast development according to modified Tanner staging. Males: Suppression is defined as regression or no progression in testicular volume and genital staging according to modified Tanner staging.
| percentage of participants | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Leuprolide Acetate - Overall |
|---|---|---|---|
| Females: Week 24 | 94.1 | 91.7 | 92.7 |
| Females: Week 48 | 88.2 | 91.7 | 90.2 |
| Females: Week 72 | 93.8 | 95.7 | 94.9 |
| Females: Week 96 | 100 | 90.5 | 94.3 |
| Females: Week 120 | 91.7 | 89.5 | 90.3 |
| Females: Week 144 | 83.3 | 87.5 | 86.4 |
| Males: Week 24 | 0 | 66.7 | 50.0 |
| Males: Week 48 | 100 | 66.7 | 75.0 |
| Males: Week 72 | 0 | 66.7 | 50.0 |
| Males: Week 96 | 100 | 66.7 | 75.0 |
| Males: Week 120 | 0 | 66.7 | 50.0 |
| Males: Week 144 | 0 | 100 | 50.0 |
Growth rate (height in centimeter/year) was calculated both prior to treatment in the study and during the study. For Baseline calculation a historical measurement of height at least 6 months prior to Screening and the Screening value was used.
| cm/year | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Leuprolide Acetate - Overall |
|---|---|---|---|
| Week 4 | -0.6 ± 9.99 | -0.9 ± 10.52 | -0.8 ± 10.19 |
| Week 12 | -0.6 ± 4.09 | -2.9 ± 5.42 | -2.0 ± 5.02 |
| Week 20 | -0.5 ± 2.61 | -3.8 ± 4.69 | -2.5 ± 4.28 |
| Week 24 | -0.5 ± 2.81 | -3.7 ± 4.28 | -2.4 ± 4.03 |
| Week 44 | -0.4 ± 2.48 | -4.1 ± 3.77 | -2.6 ± 3.76 |
| Week 48 | -0.3 ± 2.67 | -3.5 ± 4.71 | -2.3 ± 4.32 |
| Week 72 | -0.5 ± 2.09 | -4.3 ± 3.53 | -2.8 ± 3.55 |
| Week 96 | -0.6 ± 2.29 | -4.9 ± 3.43 | -3.2 ± 3.68 |
| Week 120 | -1.2 ± 1.96 | -5.6 ± 3.27 | -3.9 ± 3.54 |
| Week 144 | -1.0 ± 1.63 | -5.3 ± 2.76 | -4.0 ± 3.19 |
Bone age was assessed from radiographs of the hand and wrist by a central imaging vendor using the BoneXpert automated system. A ratio less than 1 indicates less advancement of bone age compared to chronological age.
| ratio | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Leuprolide Acetate - Overall |
|---|---|---|---|
| Week 24 | 0.5 ± 0.80 | 0.7 ± 0.56 | 0.6 ± 0.66 |
| Week 48 | 0.2 ± 1.36 | 0.6 ± 0.41 | 0.5 ± 0.93 |
| Week 72 | 0.6 ± 0.31 | 0.6 ± 0.38 | 0.6 ± 0.35 |
| Week 96 | 0.6 ± 0.32 | 0.7 ± 0.28 | 0.6 ± 0.29 |
| Week 120 | 0.5 ± 0.28 | 0.6 ± 0.34 | 0.6 ± 0.32 |
| Week 144 | 0.6 ± 0.26 | 0.6 ± 0.24 | 0.6 ± 0.24 |
Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.
| percentage of participants | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Leuprolide Acetate - Overall |
|---|---|---|---|
| Week 72 | 88.2 (63.6 to 98.5) | 96.2 (80.4 to 99.9) | 93.0 (80.9 to 98.5) |
| Week 96 | 93.3 (68.1 to 99.8) | 95.7 (78.1 to 99.9) | 94.7 (82.3 to 99.4) |
| Week 120 | 100.0 (75.3 to 100.0) | 100.0 (84.6 to 100.0) | 100.0 (90.0 to 100.0) |
| Week 144 | 100.0 (59.0 to 100.0) | 100.0 (79.4 to 100.0) | 100.0 (85.2 to 100.0) |
Estradiol concentrations were measured from blood samples taken at each study visit prior to stimulation testing.
| percentage of participants | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Leuprolide Acetate - Overall |
|---|---|---|---|
| Week 72 | 100.0 (79.4 to 100.0) | 100.0 (85.2 to 100.0) | 100.0 (91.0 to 100.0) |
| Week 96 | 100.0 (76.8 to 100.0) | 100.0 (83.2 to 100.0) | 100.0 (89.7 to 100.0) |
| Week 120 | 100.0 (71.5 to 100.0) | 100.0 (82.4 to 100.0) | 100.0 (88.4 to 100.0) |
| Week 144 | 100.0 (54.1 to 100.0) | 100.0 (78.2 to 100.0) | 100.0 (83.9 to 100.0) |
Male participants with maintenance of suppression of testosterone to \< 30 ng/dL are assessed
| percentage of participants | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Leuprolide Acetate - Overall |
|---|---|---|---|
| Week 72 | 100.0 (2.5 to 100.0) | 100.0 (29.2 to 100.0) | 100.0 (39.8 to 100.0) |
| Week 96 | 100.0 (2.5 to 100.0) | 100.0 (29.2 to 100.0) | 100.0 (39.8 to 100.0) |
| Week 120 | 100.0 (2.5 to 100.0) | 100.0 (29.2 to 100.0) | 100.0 (39.8 to 100.0) |
| Week 144 | 100.0 (2.5 to 100.0) | 100.0 (2.5 to 100.0) | 100.0 (15.8 to 100.0) |
Collected over From screening through end of study; median 949.5 and 1092.0 days for previously-treated and treatment-naïve participants, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leuprolide Acetate - Previously Treated | 0/18 (0%) | 0/18 (0%) | 18/18 (100%) |
| Leuprolide Acetate - Treament Naïve | 0/27 (0%) | 1/27 (3.7%) | 27/27 (100%) |
| Event | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve |
|---|---|---|
| AFFECTIVE DISORDERPsychiatric disorders | 0/18 | 1/27 |
| Event | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve |
|---|---|---|
| INJECTION SITE PAINGeneral disorders | 16/18 | 26/27 |
| HEADACHENervous system disorders | 9/18 | 9/27 |
| INJECTION SITE REACTIONGeneral disorders | 4/18 | 9/27 |
| PYREXIAGeneral disorders | 6/18 | 5/27 |
| COVID-19Infections and infestations | 3/18 | 9/27 |
| PAINGeneral disorders | 5/18 | 5/27 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 5/18 | 7/27 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 5/18 | 3/27 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 1/18 | 6/27 |
| INFLUENZAInfections and infestations | 4/18 | 3/27 |
| Age, Continuous(years) | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Total |
|---|---|---|---|
| Mean | 8.1 ± 1.73 | 7.7 ± 0.83 | 7.8 ± 1.27 |
| Sex: Female, Male(Participants) | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Total |
|---|---|---|---|
| Female | 17 | 24 | 41 |
| Male | 1 | 3 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 9 | 11 |
| Not Hispanic or Latino | 16 | 18 | 34 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 3 | 7 |
| White | 12 | 18 | 30 |
| More than one race | 0 | 6 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Age at onset of CPP(years) | Leuprolide Acetate - Previously Treated | Leuprolide Acetate - Treament Naïve | Total |
|---|---|---|---|
| Females | 5.9 ± 2.37 | 6.7 ± 0.99 | 6.4 ± 1.74 |
| Males | 2.1 | 6.9 ± 2.58 | 5.7 ± 3.19 |
| Overall | 5.7 ± 2.46 | 6.8 ± 1.18 | 6.3 ± 1.86 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Oct 2018 to primary completion in May 2021, 30 months.
Results were first posted in May 2023, 2 years after primary completion. A results delay was requested in May 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide